Skip to content

Preferred Stock at other companies

AngioDynamics logo
AngioDynamicsANGO
$0
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$0
Delcath Systems logo
Delcath SystemsDCTH
$0
LQD
Liquidia CorporationLQDA
$0
United Therapeutics logo
United TherapeuticsUTHR
$0
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$0

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Debt / equity2.6×
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s preferred stock?
TriSalus Life Sciences, Inc. (TLSI) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.